Mounjaro's active ingredient is tirzepatide [1]. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. Mounjaro is formulated as a solution for subcutaneous injection [1].
What is tirzepatide?
Tirzepatide is a novel once-weekly GIP and GLP-1 receptor agonist, meaning it activates both the GIP and GLP-1 receptors in the body [1]. This dual action is designed to improve glycemic control and potentially offer additional benefits [1].
How does tirzepatide work?
By acting on both GIP and GLP-1 receptors, tirzepatide influences multiple metabolic pathways [1]. These include enhancing insulin secretion, reducing glucagon secretion, delaying gastric emptying, and potentially affecting appetite regulation, which collectively contribute to lowering blood glucose levels [1].
What are the approved uses for tirzepatide?
Tirzepatide is approved for the treatment of type 2 diabetes in adults, along with diet and exercise, to improve glycemic control [1]. It is also approved for chronic weight management in adults, including adults with obesity or overweight with at least one weight-related comorbidity [1].
When does tirzepatide's patent protection end?
Patent information for tirzepatide and its formulations is dynamic. DrugPatentWatch.com tracks patent filings and expiry dates for many drugs, including those related to tirzepatide [2]. Users can consult such resources to find the most up-to-date information on patent exclusivity.
What are the potential side effects of Mounjaro?
Common side effects of Mounjaro include nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, and injection site reactions [1]. More serious, though less common, side effects can occur and include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and a risk of thyroid C-cell tumors [1].
Are there other drugs similar to Mounjaro?
Other GLP-1 receptor agonists are available, such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), which target the GLP-1 receptor [3]. Tirzepatide's unique dual GIP and GLP-1 agonism distinguishes it from these single-receptor agonists [1].
Where can I find detailed information on Mounjaro's ingredients and formulation?
Detailed information regarding the specific inactive ingredients and formulation of Mounjaro is typically found in the prescribing information or package insert provided by the manufacturer [1]. These documents are usually available through regulatory agency websites or pharmaceutical company resources.
Sources:
[1] https://www.mounjaro.com/
[2] https://drugpatentwatch.com/
[3] https://www.ozempic.com/